NuVasive Goes Red

Before you go, we thought you'd like these...
Before you go close icon

NuVasive (NAS: NUVA) reported earnings on Feb. 22. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), NuVasive met expectations on revenues and crushed expectations on earnings per share.

Compared with the prior-year quarter, revenue improved significantly and GAAP earnings per share shrank to a loss.

Margins dropped across the board.

Revenue details
NuVasive chalked up revenue of $150.2 million. The 15 analysts polled by S&P Capital IQ looked for net sales of $149.1 million on the same basis. GAAP reported sales were 16% higher than the prior-year quarter's $129.3 million.

anImage

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $0.27. The 22 earnings estimates compiled by S&P Capital IQ anticipated $0.21 per share on the same basis. GAAP EPS were -$0.24 for Q4 compared to $1.50 per share for the prior-year quarter.

anImage

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 75.3%, 680 basis points worse than the prior-year quarter. Operating margin was 5.6%, 320 basis points worse than the prior-year quarter. Net margin was -6.7%, 5,460 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $142.5 million. On the bottom line, the average EPS estimate is $0.18.

Next year's average estimate for revenue is $614.3 million. The average EPS estimate is $0.97.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 162 members out of 182 rating the stock outperform, and 21 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give NuVasive a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on NuVasive is outperform, with an average price target of $24.56.

The health-care investing landscape is littered with also-rans and a few major winners. Is NuVasive the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Get instant access to this free report.

At the time this article was published

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners